{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:02:18Z","timestamp":1785816138635,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013291","name":"Huazhong University of Science and Technology Tongji Medical College","doi-asserted-by":"publisher","award":["2020003"],"award-info":[{"award-number":["2020003"]}],"id":[{"id":"10.13039\/501100013291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015640","name":"Tongji Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015640","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170223"],"award-info":[{"award-number":["82170223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ymthe.2024.11.013","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T08:11:39Z","timestamp":1731053499000},"page":"2768-2777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed\/refractory multiple myeloma"],"prefix":"10.1016","volume":"33","author":[{"given":"Qiuxia","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songbai","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-7133","authenticated-orcid":false,"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.11.013_bib1","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: a comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2024.11.013_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2024.11.013_bib3","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2024.11.013_bib4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s40265-017-0837-7","article-title":"Daratumumab: A Review in Relapsed and\/or Refractory Multiple Myeloma","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.11.013_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ymthe.2024.11.013_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.11.013_bib7","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib8","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed\/Refractory Multiple Myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib9","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.11.013_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-023-01479-5","article-title":"BCMA-targeted CAR-T cell therapies in relapsed and\/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting","volume":"16","author":"Wu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib11","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.013_bib12","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib14","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.11.013_bib15","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.803693","article-title":"A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy","volume":"13","author":"Mu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib17","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-Generation CAR T-cell Therapies","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2024.11.013_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.11.013_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115691","article-title":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","volume":"168","author":"Yuti","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2024.11.013_bib20","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.11.013_bib21","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.013_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.thromres.2023.05.016","article-title":"Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed\/refractory multiple myeloma","volume":"227","author":"Li","year":"2023","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ymthe.2024.11.013_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102479","article-title":"Toxicities following CAR-T therapy for hematological malignancies","volume":"111","author":"Hernani","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ymthe.2024.11.013_bib24","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib25","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/14787210.2021.1855143","article-title":"CAR-T cell therapy and infection: a review","volume":"19","author":"Bupha-Intr","year":"2021","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"10.1016\/j.ymthe.2024.11.013_bib26","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.11.013_bib27","doi-asserted-by":"crossref","first-page":"304.e1","DOI":"10.1016\/j.jtct.2022.03.005","article-title":"Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Transpl. Cell. Ther."},{"key":"10.1016\/j.ymthe.2024.11.013_bib28","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/1078-0432.CCR-21-0168","article-title":"Antidrug Antibodies and Drug Development: Challenges in the Immunotherapy Era","volume":"27","author":"de Sp\u00e9ville","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.013_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.11.013_bib31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00280-022-04418-2","article-title":"Anti-drug antibodies in the current management of cancer","volume":"89","author":"Borreg\u00f3n","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib32","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3390\/cimb44040098","article-title":"sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma","volume":"44","author":"Seipel","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11523-021-00821-6","article-title":"Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed\/Refractory Multiple Myeloma Starting New Therapy","volume":"16","author":"Bujarski","year":"2021","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib34","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2024.11.013_bib36","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1373\/clinchem.2005.053272","article-title":"Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies","volume":"51","author":"Moxness","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymthe.2024.11.013_bib37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.coi.2008.06.011","article-title":"Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement","volume":"20","author":"Aarden","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.013_bib38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jmoldx.2020.02.007","article-title":"Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR","volume":"22","author":"Lou","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ymthe.2024.11.013_bib39","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA\/EBMT Consensus Grading and Best Practice Recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.013_bib40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624007408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624007408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:07:14Z","timestamp":1759612034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624007408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1525001624007408"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.11.013","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed\/refractory multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}